^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Focus V (anlotinib)

    i
    Other names: AL3818, AL-3818, ALTN, AL 3818
    Company:
    Advenchen, Sino Biopharm
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    1d
    Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, West China Hospital
    New P2 trial
    |
    Focus V (anlotinib) • Kaitanni (cadonilimab)
    1d
    QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P2/3, N=120, Not yet recruiting, Sun Yat-sen University
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Focus V (anlotinib) • Qibeian (iparomlimab/tuvonralimab)
    5d
    Anlotinib Capsules in the Treatment for IPF/PF-ILDs (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, First Affiliated Hospital of Wenzhou Medical University | Recruiting --> Active, not recruiting | Phase classification: P2/3 --> P2 | Trial primary completion date: Mar 2026 --> Sep 2026
    Enrollment closed • Phase classification • Trial primary completion date
    |
    Focus V (anlotinib)
    6d
    ALTER-UC-011: Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy (clinicaltrials.gov)
    P2, N=144, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Focus V (anlotinib) • Andewei (benmelstobart)
    6d
    RAOS: Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC) (clinicaltrials.gov)
    P=N/A, N=25, Recruiting, Nanfang Hospital, Southern Medical University
    New trial
    |
    Avastin (bevacizumab) • Focus V (anlotinib)
    7d
    Primary large cell neuroendocrine carcinoma of pulmonary artery: a case report and literature review (PubMed, Zhonghua Jie He He Hu Xi Za Zhi)
    The patient subsequently received etoposide plus cisplatin (EP), irinotecan, and third-line combination therapy of serplulimab, anlotinib, and temozolomide. Radical surgery combined with platinum-based chemotherapy constitutes the mainstay of treatment. Molecular testing can provide a basis for personalized therapy, and multiline comprehensive treatment may offer prolonged survival benefits for patients.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation • NRAS exon 3 mutation
    |
    cisplatin • Focus V (anlotinib) • temozolomide • etoposide IV • irinotecan • Hetronifly (serplulimab)
    9d
    NAET4-SNACC: Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, Eye & ENT Hospital of Fudan University
    New P2 trial
    |
    Focus V (anlotinib) • epirubicin
    13d
    FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)
    P2, N=716, Recruiting, Fudan University | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)
    |
    Herceptin (trastuzumab) • carboplatin • Focus V (anlotinib) • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • Andewei (benmelstobart) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Idafang (ivonescimab) • bulumtatug fuvedotin (9MW2821) • AiRuiLi (adebrelimab) • IBI-354 • SHR-4602 • TQB2102 • TQB2868 • anbenitamab repodatecan (JSKN003) • tizetatug rezetecan (SHR-A1921)
    13d
    SPARE-04: Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=274, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Focus V (anlotinib) • Anniko (penpulimab-kcqx)
    14d
    Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma (clinicaltrials.gov)
    P2, N=29, Completed, Second Affiliated Hospital of Nanchang University | Recruiting --> Completed | Trial completion date: Dec 2026 --> Sep 2025 | Trial primary completion date: Dec 2026 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr)
    16d
    Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis. (PubMed, Nat Commun)
    DURABLE was a prospective, multicenter, open-label, randomized, phase II trial (NCT04985851) that evaluated the efficacy and safety of durvalumab plus anlotinib as consolidative maintenance therapy following first-line durvalumab plus platinum-etoposide chemotherapy in ES-SCLC. While similar efficacy between the two groups was observed in patients with high antigen presenting capacity or high bTMB. These findings suggest that durvalumab plus anlotinib might be an effective and well-tolerated maintenance treatment option in ES-SCLC.
    P2 data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    Imfinzi (durvalumab) • Focus V (anlotinib) • etoposide IV
    19d
    QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=34, Recruiting, Jiangsu Cancer Institute & Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Focus V (anlotinib) • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)